Alongside a deeper collaboration with the not-for-profit system, Omada expects the funds to fuel expansion of its integrated digital care program.
Digital chronic disease management company Omada Health has added onto June’s $73 million funding round with a new strategic investment from Intermountain Ventures. The terms of the deal were not disclosed.
WHAT THEY DO
Omada pitches its digital coaching programs as a scalable and convenient approach to chronic disease management. The company’s products address hypertension, Type 2 diabetes, mental health conditions and other health needs. The company also implements connected technology to track participants and hold them accountable — for instance, a wireless scale, a pedometer, and a mobile app to track food and activity for its diabetes program.
Read More: https://www.mobihealthnews.com/news/north-america/omada-health-receives-strategic-investment-intermountain-ventures
Via: MobiHealthNews Via: Carilion Clinic Joe Wright of Wytheville went to his ophthalmologist with a case of pink eye. What Joe, 83, came away with was, in his own words, “a pretty big shock.” Via: Yahoo! Finance Nearly 800,000 Americans have a stroke each year. Sadly, about 140,000 of them will pass away from the event. That makes stroke the fifth most common cause of death. These numbers speak volumes about our desperate need for new treatment options. Via: GlobeNewswire SUNNYVALE, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of a public offering of 4,200,000 shares of its common stock sold by selling stockholders, and the exercise in full of the underwriters’ option to purchase 630,000 additional shares of common stock from certain selling stockholders, at a public offering price of $39.50 per share. Silk Road Medical did not receive any proceeds from the sale of the shares of common stock by the selling stockholders. Via: GlobeNewswire SUNNYVALE, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the pricing of an upsized secondary public offering of 4,200,000 shares of its common stock by certain selling stockholders at a public offering price of $39.50 per share. In addition, certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 630,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders. The offering is expected to close on August 13, 2019, subject to the satisfaction of customary closing conditions. Via: GlobeNewswire SUNNYVALE, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of 3,500,000 shares of its common stock by certain selling stockholders. In addition, certain selling stockholders expect to grant the underwriters a 30-day option to purchase an additional 525,000 shares of its common stock in the offering. Silk Road Medical will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling stockholders. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Via: PR Newswire Digital Care Leader's Integrated Program Supports Individuals Dealing with Chronic Disease, Mental Health Issues Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early Pregnancy6/17/2019
Via: PR Newswire -- Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening -- Final results of the ROADSTER 2 post-market approval study of TCAR: Interview with Vikram S Kashyap6/15/2019
Via: VascularNews Vikram S Kashyap, co-principal investigator of the ROADSTER 2 trial, today presented the final 30-day outcomes of the post-market approval study in a late-breaking trial session at the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM; 12–15 June, National Harbor, USA). The data show the sustained safety and efficacy of transcarotid artery revascularisation (TCAR) with Silk Road Medical’s Enroute system. In this interview, Kashyap speaks to Vascular News about the procedure, and how TCAR trialists are hoping to make an impact for patients needing carotid revascularisation. Via: GlobeNewswire Final Results Presented in Late-Breaking Session at Society for Vascular Surgery 2019 Vascular Annual Meeting |
Archives
October 2023
|